...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Exempt Distributions

1) 2023-08-10 (Alberta)

Promissory Note: $167,612.50

With 225,000 warrants @ $1.00, Expire 2023-08-10. The expiry date makes no sense!! It must be a misprint. It has to be, 2028-08-10.

2) 2023-08-28 (Alberta)

Promissory Note: $472,973.00

With 600,000 warrants @ 1.02 expire 2028-08-28.

3) 2023-09-13 (Alberta)

Promissory Note: $271,020.00

With 350,000 warrants @ $1.02 expire, 2028-09-13

 

All exemptions relied on NI 45-106 2.3 (Accredited Investor) out of Alberta.

 

Koo

 

 

 

Share
New Message
Please login to post a reply